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http://www.springerplus.com/content/2/1/562RESEARCH Open Accessp31comet inactivates the chemically induced
Mad2-dependent spindle assembly checkpoint
and leads to resistance to anti-mitotic drugs
Toshiyuki Habu* and Tomohiro MatsumotoAbstract
Mad2 is a key component of the spindle assembly checkpoint (SAC) that delays the onset of anaphase until all
kinetochores are attached to the spindle. It binds to Cdc20 and prevents it from promoting destruction of an
anaphase inhibitor, Securin. Previously, we showed that a Mad2-binding protein, p31comet, formed a complex with
Mad2 upon the completion of spindle attachment. Here, we showed that the overexpression of p31comet can
abolish the Mad2-dependent SAC that is induced by anti-mitotic drugs, including nocodazole, taxol, and monastrol;
these drugs, except monastrol, cause aneuploidy in HeLa cells. In the absence of Eg5, which is a target of
monastrol, overexpression of p31comet caused premature destruction of Securin and premature sister chromatid
separation, but it did not cause aneuploidy. These results indicated that Eg5 kinesin function might be required for
checkpoint exit and mitotic progression. Moreover, overexpression of p31comet led to resistance against apoptosis
that was induced by nocodazole and taxol in human cells, and taxol resistance was dependent on the p31comet/
Mad2 protein expression level ratio of in cancer cell lines. These results indicated that p31comet is an indicator of
resistance to anti-mitotic drugs in cancer cells.
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The spindle assembly checkpoint (SAC) is a surveillance
mechanism that delays the onset of anaphase until the
completion of the spindle microtubule attachment to all
kinetochores during mitosis (Elledge 1998; Kops et al.
2005; Nasmyth 2005). Mad2 is a master regulator of the
checkpoint and is found in a complex with its target,
Cdc20, which is a co-activator of anaphase promoting
complex or cyclosome (APC/C), from prometaphase to
metaphase. The association and inhibition of Cdc20 by
SAC to delay the proteolysis of Securin and cyclin B1,
appears to be a central process in the signaling SAC
cascade (Fang et al. 1998; Hwang et al. 1998; Kim et al.
1998; Shah and Cleveland 2000). Mad2 has two
conformations, ‘open’ (O-Mad2) and ‘close’ (C-Mad2)
(Luo et al. 2004; Mapelli et al. 2007). The Mad1-C-Mad2
complex acts as a template and recruits O-Mad2 to con-
vert Mad2 molecules into Cdc20 inhibitors (C-Mad2-* Correspondence: habu.toshiyuki.6x@kyoto-u.ac.jp
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reproduction in any medium, provided the origCdc20) (Musacchio and Salmon 2007). C-Mad2-Cdc20
binds to the BubR1-Bub3 complex, forming the mitotic
checkpoint complex (MCC). By binding to APC/C, the
MCC inhibits the ubiquitylation activity onto Securin
and Cyclin B1 (Sudakin et al. 2001).
Upon the completion of spindle attachment, Mad2 di-
minishes from the kinetochores. The microtubule-
kinetochore interaction is thought to silence SAC signal.
p31comet, which we identified by the yeast two-hybrid
system as a human Mad2-binding protein, is one of the
candidates for the silencer of SAC (Habu et al. 2002).
We showed that the formation of the p31comet-Mad2
complex coincides with the dissociation of Mad2 from
Cdc20, and the overexpression of p31comet abolishes the
SAC function in a Mad2-Cdc20 complex-dependent
manner. Additionally, p31comet can bind to only the
Cdc20-bound conformation of Mad2 (C-Mad2), and can
block the biochemical function of C-Mad2 in vitro
(Xia et al. 2004) and can compete with O-Mad2. From
these observations, it has been proposed that p31comet
acts as an inhibitory cap on the Mad2-C-Mad2 complexr. This is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Habu and Matsumoto SpringerPlus 2013, 2:562 Page 2 of 15
http://www.springerplus.com/content/2/1/562(Mapelli et al. 2006; Musacchio and Salmon 2007). In
addition to the model, it has been proposed that
p31comet contributes to SAC silencing by promoting
Cdc20 ubiquitylation, leading to the disassembly of the
MCC (Jia et al. 2011; Varetti et al. 2011). p31comet also
promotes the dissociation of Cdc20 from BubR1 in an
ATP-dependent manner (Teichner et al. 2011), and this
dissociation is co-related to Cdc20 phosphorylation
(Miniowitz-Shemtov et al. 2012). Recent studies showed
that p31comet promotes an early step in MCC disassem-
bly, extracting Mad2 and leaving behind a BubR1-Bub3-
Cdc20 complex (Hagan et al. 2011; Westhorpe et al.
2011). Taken together, p31comet plays a role in silencing
the Mad2-dependent SAC.
The chemical inhibitors of mitotic spindle microtu-
bules are commonly used for cancer therapy, and experi-
mental approaches to observe spindle function, and
mitosis studies (Mayer et al. 1999; Kapoor et al. 2000;
Skoufias et al. 2001; Sudo et al. 2004; Tao et al. 2005; Shi
et al. 2008). Nocodazole and vinca alkaloids accelerate
microtubule depolymerization and therefore generate
unattached kinetochores. Taxol interferes with micro-
tubule dynamics, though the sister kinetochores are
closer together and remain bound to microtubules.
These observations indicate that these agents generate a
loss of kinetochore tension. In contrast, monastrol and
KSP-IA are inhibitors of Eg5, which is a mitotic spindle
motor protein belonging to the kinesin superfamily. Eg5
is required for centrosome separation and the formation
of bipolar spindle in mitosis; therefore, inhibition of Eg5
causes mitotic arrest with the monopolar spindles
(Kapoor et al. 2000). Monastrol also reduces inter-
kinetochore tension because many attachments in the
monopolar spindles are syntelic.
To examine p31comet function in human cells, drug
treatment approaches to activate SAC were used. The
overexpression of p31comet could abolish the nocodazole
and taxol-induced SAC and results in aneuploid cells,
but the monastrol-induced SAC does not result in aneu-
ploidy although Securin destruction was observed. HeLa
cells whose Eg5 kinesin has been depleted by RNA inter-
ference (RNAi) caused the Mad2-dependent mitotic ar-
rest similar to monastrol treatment. When p31comet was
overexpressed in Eg5-depleted cells, the cells arrested in
mitosis with the same kinetics as Eg5-depleted cells, des-
pite the destruction of Securin and the dissociation of
sister chromatids. These results indicated that the over-
expression of p31comet could overcome drug-induced
Mad2-dependent SAC activation, and it might catalyze
Mad2 inactivation during mitosis. Furthermore, the
overexpression of p31comet induced resistance to apop-
tosis that was induced by nocodazole and taxol in
human cancer cells independent on p53 function. The
expression level of p31comet protein in various cancer celllines was observed, and the ratio of p31comet/Mad2 pro-
tein expression levels correlated with taxol sensitivity.
These results may indicate a model to explain the roles
of SAC and aneuploidy in tumorigenesis.
Results
p31comet binding to Mad2 protein
To verify the binding to Mad2 protein, series of p31comet
fragments tagged with EGFP was overexpressed in HeLa
cells (Figure 1a and b), and immunoprecipitation was
performed with anti-GFP antibody. As our previous
study using a yeast two hybrid assay showed (Habu et al.
2002), Mad2 protein was immunoprecipitated with full-
length, A, and B fragments of p31comet but not with C
and D fragments (Figure 1b). The position between
amino acids 55 and 81 of p31comet might be responsible
for binding to Mad2 protein. Full length p31comet can
abolish the SAC function in the presence of nocodazole
in a Mad2-dependent manner (Habu et al. 2002). The
same assay was performed in the presence of nocodazole
using a series of p31comet fragments (Figure 1c). When
overexpressed, cells with 8 N DNA content were ob-
served in fluorescence-activated cell sorting (FACS) ana-
lysis with the same kinetics with fragments (full-length,
A, B) that could bind to Mad2 in vivo (full-length:
40.8%, A: 41.7%, and B: 36.4%), but the same levels were
not observed for fragments C and D, and EGFP only
(C: 19.1%, D: 19.2%, and EGFP: 13.7%), which could not
bind to Mad2 protein. An amino-terminal fragment of
p31comet (1-80 amino acids), which could bind to Mad2
using a yeast two-hybrid assay (Habu et al. 2002), also
could override nocodazole-induced SAC (Additional
file 1: Figure S1). In addition to these data, L76A/L77A
mutant, in which was located in deleted region in frag-
ment C of p31comet, could not override SAC (Additional
file 1: Figure S1). These data indicated that p31comet-dir-
ect binding to Mad2 protein might be important for
SAC function.
The effect of antimitotic drugs in p31comet overexpressing
cells
Antimitotic drugs (nocodazole, taxol, and monastrol)
were used to observe SAC function in vivo because each
drug shows a different effect on spindle morphology and
checkpoint machinery. To test the effect of each drug in
p31comet overexpressing cells, the cells infected with
EGFP or EGFP- p31comet adenoviruses were treated with
serial dilutions of each drug as indicated in Figure 2a,
and incubated for 24 h. The cell cycle progression of
these cells was analyzed by FACS, and the mitotic status
was monitored by detecting the accumulation of Securin
and the phosphorylation of Cdc27 protein (Tugendreich
et al. 1995; Zou et al. 1999). When the cells overexpress-
ing p31comet were treated with nocodazole, the
Figure 1 p31comet binding to Mad2 protein. (a) Diagrams of N-terminal deletion p31comet fragments. (b) p31comet binding to Mad2 protein.
EGFP, EGFP-tagged full-length p31comet, and a series of N-terminal deletion EGFP-tagged p31comet were overexpressed in HeLa cells by
adenovirus infection and the expression level of each protein was monitored by western blotting with anti-GFP antibody, using anti-Mad2 and
anti-EB1 antibodies for loading controls. The cell extracts overexpressing each protein were prepared for immunoprecipitation with anti-GFP
antibody, followed by western blotting with anti-Mad2 and anti-GFP antibodies. (c) Fluorescence-activated cell sorting (FACS) analysis of the cells
overexpressing EGFP-tagged full-length p31comet and a series of N-terminal deletion EGFP-tagged p31comet in the presence of nocodazole
(100 ng/mL). A population of >4 N DNA content in the cells was shown.
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Figure 2 The effect of p31comet overexpression on anti-mitotic drug-treated cells. (a) FACS analysis of p31comet-overexpressing cells treated
with anti-mitotic drugs (nocodazole, taxol, and monastrol). Cells were infected with EGFP or EGFP-p31comet adenovirus for 24 h, washed with
fresh medium twice, and treated with anti-mitotic drugs at the indicated concentration for 24 h. These cells were prepared for FACS analysis. A
population of >4 N DNA content in the cells was shown. (b) Western blotting analysis of p31comet-overexpressing cells treated with anti-mitotic
drugs. Drug-treated cell extracts were subject to western blotting with anti-Cdc27 and anti-Securin antibodies to monitor the cell cycle status,
anti-GFP antibody for EGFP and EGFP-p31comet, and anti-Mad2 antibody for a loading control.
Habu and Matsumoto SpringerPlus 2013, 2:562 Page 4 of 15
http://www.springerplus.com/content/2/1/562overexpression of p31comet led the appearance of cell
fraction with 8 N DNA content (12.3-17.1%), but this
was not observed with the overexpression of EGFP
(1.6-6.2%) (Figure 2a). Depending on the dosage of
nocodazole, the cell fraction with 8 N DNA content de-
creased. In the treatment with taxol, the overexpression
of p31cometovercame the taxol-induced SAC (EGFP-p31comet: 21.2-31.3%, EGFP: 8-16.4%) (Figure 2a). With
overexpressed p31comet, no accumulation of Securin,
and the decreased phosphorylation levels of Cdc27 pro-
tein were observed with the nocodazole treatment
(Figure 2b). In contrast, the monastrol-treatment
induced accumulation in mitosis, which is Mad2-
dependent mitotic arrest (Additional file 1: Figure S2),
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cell cycle profiles between EGFP and EGFP-p31comet
overexpression were not observed by FACS analysis,
although the sub-G1 fraction was partially suppressed in
EGFP-p31comet overexpressing cells (Figure 2a, lower
panels). In HeLa cells, the low-dosage monastrol treat-
ment induced apoptosis. From western blotting analysis,
no accumulation of Securin, and the decreasing phos-
phorylation level of Cdc27 protein were observed in
these cells with the nocodazole treatment despite the ac-
cumulation in mitosis that was observed by FACS ana-
lysis of p31comet overexpressing cells (Figure 2a and b).
To confirm the monastrol effect in p31comet overexpress-
ing cells, the cells that were treated with different doses
of nocodazole for 6 h were incubated in monastrol
containing medium (50 nM) for 18 h (Additional file 1:
Figure S3). In this case, the accumulation of G2/M
fraction cells was also observed in the cells overexpress-
ing EGFP and EGFP-p31comet. Nocodazole treatment of
monastrol-pretreated cells was also examined. With this
treatment, the accumulation of the cells with 4 N DNA
contents was observed as it was with a single round of
monastrol treatment (data not shown). These data indi-
cated that p31comet-overexpression could inactivate SAC
that is induced by the antimitotic drugs nocodazole and
taxol but not monastrol.
Localization of Mad2 and microtubule array of in p31comet
overexpressing cells treated with antimitotic drugs
Because p31comet-overexpression inactivates SAC that
are induced with antimitotic drugs, we observed the
localization of Mad2 and the array of microtubules in
the cells. HeLa cells stably expressing EGFP-tagged
Mad2 were treated with EGFP or EGFP-p31comet adeno-
viruses and were exposed to the antimitotic drugs. In
p31comet-overexpressing cells treated with nocodazole,
the signals of EGFP-Mad2 on unattached kinetochores
were detectable as EGFP-overexpressing cells (Figure 3a,
upper panels) in mitosis, but the signals were diffused
into the cytoplasm in enlarged giant cells (Figure 3a,
upper right panel), which appeared predominantly in
EGFP- p31comet overexpressing cells. In the cells treated
with taxol, the signals of EGFP-Mad2 on unattached
kinetochores were detectable as EGFP-overexpressing
cells, although a lower number of signals was detectable
compared with the cells treated with nocodazole, which
was also reported in a previous study (Figure 3)
(Skoufias et al. 2001). Taxol treatment p31cometoverex-
pressing cells induced multinucleated cells rather than
aneuploid cells (Figure 3a-c). To address aneuploidy
and/or multinuclei in p31comet-overexpressing cells,
chromosome spread analysis was performed. Although
well isolated mitotic condensed chromosomes were
observed in EGFP-overexpressing cells, no mitoticchromosomes were observed in p31comet-overexpressing
cells because there was no mitotic arrest (Additional
file 1: Figure S4a and b). In contrast, the cells arrested at
prometaphase in both EGFP and EGFP-p31comet overex-
pressing cells, when the cells were exposed to monastrol
(Figure 3a and b). The signals of EGFP-Mad2 were de-
tected on one sister kinetochore in the majority of the
control cells as reported (Figure 3a, lower, left panel).
When p31comet was overexpressed in the cells, the sig-
nals seemed to be positive on both sister kinetochores
(Figure 3a, lower, right panel). Based on statistical ana-
lysis, 47% of arrested cells were positive on both sister
kinetochores for Mad2 (n = 55), compared with 16% in
EGFP overexpressing cells (n = 35).
Next, immunostaining with α-tubulin antibody was ex-
amined in p31comet overexpressing cells treated with
these drugs. The array of microtubules was not detect-
able in both EGFP and p31comet-overexpressing cells
with nocodazole treatment because of the depolymeri-
zation of the microtubules (Figure 3b). The taxol treat-
ment increased the stability of microtubules; therefore,
well-bundled microtubules were observed in interphase
and/or mitotic cells overexpressing both EGFP and
p31comet (Figure 3b and c). Because the taxol treatment
causes centrosome amplification (Wang et al. 2000), it
resulted in multinucleated cells in p31comet overexpress-
ing cells rather than giant cells (Figure 3a-c, Additional
file 1: Figure S4). In contrast, when the cells were ex-
posed to monastrol, monoasters array of microtubules
was observed using the p31comet overexpression as the
control (Figure 3b), although Mad2 seemed to localize
on both sister kinetochores. This indicated that p31comet
overexpression caused SAC inactivation in the presence
of nocodazole or taxol, but it did not affect Mad2
localization or microtubule arrays and led to aneuploid
or multinucleated cells. As observed in monastrol-
treatment experiments, p31comet could inactivate SAC
and caused premature destruction of Securin in spite of
Mad2 kinetochore localization, although cell cycle arrest
during mitosis.
The SAC inactivation activity of p31comet in Eg5-depleted
cells
p31comet overexpression could not overcome mitotic ar-
rest in monastrol treated cells like it could in nocodazole
and taxol treated cells. Although the destruction of
Securin protein and the phosphorylation of Cdc27 were
observed in p31comet-overexpressing cells treated with
monastrol, the cells showed a prolonged arrest. Because
Eg5 kinesin is the target of monastrol, p31comet was
overexpressed in cells, in which Eg5 was depleted with
siRNA (Figure 4a). As shown in the control experiment
in Figrue 4b, Eg5-depletion with siRNA induced G2 or
mitotic arrest similar to monastrol-treatment 36 h after
Figure 3 (See legend on next page.)
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Figure 3 Localization of Mad2 and microtubule arrays of in p31comet-overexpressing cells in the presence of anti-mitotic drugs. (a)
Mad2 localization in p31comet overexpressing cells. HeLa cells stably expressing EGFP-Mad2 were infected with EGFP or EGFP-p31comet adenovirus
for 24 h, washed with fresh medium twice, and treated with anti-mitotic drugs at the indicated concentration for 24 h described in Figure 2. Cells
were fixed with 3% paraformaldehyde and counterstained with Hoechest33324 for DNA (shown in blue). EGFP-Mad2 was shown in green. Cells
were treated with the following drugs: (upper panels) nocodazole, (middle panels) taxol, and (lower panels) monastrol. EGFP (left panels) or
EGFP-p31comet-expressing (right panels) cells were shown. (b) Array of microtubules in p31comet-overexpressing cells. HeLa cells were infected
with EGFP or EGFP-p31comet adenovirus for 24 h, washed with fresh medium twice, and treated with anti-mitotic drugs at the indicated
concentration for 24 h. Cells were fixed with cold methanol, stained with β-tubulin antibody for microtubules (shown in green), and
counterstained with Hoechest33324 for DNA (shown in blue). Cells were treated with the following drugs: (upper panels) nocodazole, (middle
panels) taxol, and (lower panels) monastrol. EGFP (left panels) or EGFP-p31comet-expressing (right panels) cells were shown. Note: EGFP and EGFP-
p31comet signals were not detectable in this condition. (c) Array of microtubules and Mad2 localization in p31comet overexpressing cells. HeLa cells
were infected with EGFP-p31comet adenovirus for 24 h and, treated with Taxol for 24 h. Cells were fixed with cold methanol, stained with Mad2
(upper panel) or α-tubulin (lower panel) antibodies (shown in green), and counterstained with Hoechest33324 for DNA (shown in blue).
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of apoptotic cell death after 42 h (Figure 4d, lower left
panel). Western blotting was performed to confirm the
Eg5-depletion (Figure 4c, lanes 4-6), and over 90% of Eg5
protein were depleted with this siRNA compared to
control siRNA (Figure 4c, lanes 1-3). When p31comet was
overexpressed in the Eg5-depleted cells, the cells arrested
in mitosis like cells with EGFP overexpression, and
cells with 8 N DNA content were not observed with
monastrol-treatment (Figure 4b). Forty-two hours after
transfection, p31comet overexpression in the Eg5-depleted
cells resulted in apoptosis with similar kinetics as EGFP
overexpression (Figure 4d, lower panels). Although the
Eg5-depleted cells overexpressing p31comet arrested in
mitosis, the protein level of Securin was lower than that of
the control cells overexpressing EGFP-p31comet with
monastrol treatment (Figure 4c, lanes 5 and 6). Next,
chromosome spread analysis was used to examine the Eg5-
depleted HeLa cells overexpressing EGFP or p31comet
(Figure 4e and f). We categorized the chromosome spreads
into four different groups (Figure 4e) and measured the
numbers 36 h after transfection (Figure 4f). Interestingly,
the overexpression of p31comet caused premature release of
sister chromatid cohesion (Figure 4e, category 2 and 4),
but the overexpression of EGFP did not (Figure 4e, cat-
egory 1). Forty-one percent of cells (Figure 4e, category 2)
and 38% of cells (Figure 4e, category 4) showed premature
separation of sister chromatid; strikingly, chromosomes of
category 3 and 4 were elongated compared with those of
category 1 and 2. The partial decondensation might begin
in the p31cometoverexpressing cells with depleted Eg5 after
the inactivation of SAC. These data indicated that p31comet
inactivated SAC, but progression to next cell cycle did not
occur in the absence of Eg5 function, which was similar to
monastrol treatment.
Resistance to anti-mitotic drugs in p31comet
overexpressing cells
Taxanes including taxol are used for chemotherapy of
several cancers. Taxol can bind to microtubules andsuppress the microtubule dynamics; therefore, cells
treated with this drug arrest in mitosis, and prolonged
arrest with the drug induces apoptosis. In some cases,
cells in prolonged arrest eventually escape the mitotic
arrest and exit mitosis through adaptation process
(Wang et al. 2000). The adapted cells are able to con-
tinue growing and become polyploidy cells without
apoptosis (Weaver and Cleveland 2005). The adaptation
process remains unclear. Because p31comet overexpres-
sion accelerated aneuploidy in the presence of anti-
mitotic drugs, we examined the effects of p31comet
overexpression on resistance to anti-mitotic drugs
(Figure 5). HeLa cells that were infected with EGFP or
EGFP-p31comet adenoviruses were treated with anti-drugs
(100 ng/mL nocodazole, 100 nM taxol, 100 nM monas-
trol) for 24 or 48 h as indicated in Figure 2, and the apop-
totic cells were monitored (Figure 5a). With nocodazole
treatment for 48 h, HeLa cells overexpressing p31comet
remained viable and exhibited only 24% apoptotic cells
compared to 77.1% for apoptotic cells in EGFP overex-
pressing cells. Similar results were observed with taxol
treatment (18% for p31comet-overexpression vs. 62% for
EGFP-overexpression). Because HeLa cells overexpressing
p31cometdid not override monastrol-induced mitotic arrest
(Figures 2 and 4), the EGFP-and p31comet-overexpressing
cells treated with monastrol underwent apoptosis with the
same kinetics (Figure 5a). Next, we examined the effect of
the continuous treatment with these drugs. Two hundred
cells overexpressing EGFP or EGFP-p31comet were seeded
into fresh medium with anti-mitotic drugs, and cell
survival was monitored by counting cells that were not
stained by trypan blue dye at indicated time points in
Figure 5b. In the short treatment experiment, the viabil-
ity of EGFP-p31comet overexpressing HeLa cells that were
treated with nocodazole or taxol was dramatically ele-
vated, but the same observation was not made with
monastrol (Figure 4b). These results indicated that
p31comet-overexpression induced the resistance to micro-
tubule poisons by inactivating the Mad2-dependent SAC
directly.
Figure 4 The effect of p31comet overexpression in Eg5-depleted cells. (a) Scheme of p31comet overexpression in Eg5-depleted cells. (b) FACS
analysis of p31comet-overexpressing cells with Eg5-depletion. Cells treated with Eg5 siRNA or control siRNA were infected with EGFP or EGFP-
p31comet adenovirus and prepared for FACS analysis. A population of >4 N DNA content in the cells was shown. (c) Western blotting analysis of
p31comet-overexpressing cells with Eg5-depletion. The siRNA-treated cell extracts were subject to western blotting with anti-Eg5 antibody to
monitor Eg5 depletion, anti-Securin antibody to monitor cell cycle status, anti-GFP antibody for EGFP and EGFP-p31comet, and anti-Mad2 antibody
for a loading control. (d) Apoptosis analysis of Eg5-depleted cells. Eg5-depleted cells overexpressing EGFP or EGFP-p31comet were subject to
apoptosis analysis with Multicaspase detection kit. A population of apoptotic cells in each treatment was shown. (e, f) Chromosome analysis of
p31comet-overexpressing cells with Eg5-depletion. The arrested cells were fixed in methanol/acetone solution and spread onto glass slides. The
chromosome spreads were stained with Giemsa dye and observed with microscopy. Typical chromosome morphologies were shown in (e) and
categorized into four types. Fifty chromosome spreads were observed and scored.
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Mad2 and p53 double knockout mice and embryonic
fibroblast cells were viable and exhibited chromosomal
instability (Burds et al. 2005), although Mad2 single
knockout mice were lethal (Michel et al. 2001). Thesestudies indicated that p53 protein guarded the chromo-
somal loss and/or gain with SAC machinery. To address
the p53 dependency in aneuploidy from p31comet overex-
pression, p31comet was overexpressed in HCT116 cells,
which are colorectal carcinoma cells, and the p53-
Figure 5 (See legend on next page.)
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Figure 5 The effect of p31comet overexpression on drug-induced apoptotic cell death. (a) Apoptosis analysis of p31comet-overexpressing
cells with continuous treatment by anti-mitotic drugs. HeLa cells overexpressing EGFP or EGFP-p31comet and treated with anti-mitotic drugs were
subject to apoptosis analysis with MultiCaspase detection kit. (b) Cell survival analysis of p31comet overexpressing cells with continuous treatment
by anti-mitotic drugs. HeLa cells overexpressing EGFP or EGFP-p31comet and treated with anti-mitotic drugs were subject to trypan blue exclusion
to counte live cells at the indicated time points. (c) The FACS analysis of p31comet-overexpressing HCT116 cells. HeLa or HCT116 cells were
infected with EGFP or EGFP p31comet adenovirus for 24 h, and the viruses were washed out with fresh medium. The infected cells were incubated
with or without nocodazole for 24 h and prepared for FACS analysis. A population of >4 N DNA content in the cells was shown.
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tein is less or not expressed in HeLa cells compared with
normal cells, p31comet-overexpressing HeLa cells that
were treated with anti-mitotic drugs were able to over-
ride SAC like Mad2 and p53 double knockout mice and
the cells (Figure 5b and c). Interestingly, p31comet-over-
expressing HCT116 cells in the presence of nocodazole
were also able to lead aneuploidy like HeLa cells with
similar kinetics (Figure 5c). H1299 cells, which are non-
small cell lung cancer cells do not express p53 protein,
were used to overexpress p31comet in the presence of
anti-mitotic drugs. Using these cells, the overexpression
of p31comet did not override the nocodazole-induced SAC,
but it could override taxol-induced SAC (Additional file 1:
Figure S5) in a similar manner like HeLa and HCT116
cells. These results suggested that cells overexpressing
p31comet in the presence of spindle poisons exit mitosis in
a p53-independent adaptation pathway.
Expression of p31comet in cancer cell lines and resistance
against taxol
The overexpression of p31comet contributed to aneu-
ploidy and resistance to anti-mitotic drugs. To address
p31comet function with respect to drug sensitivity, we ob-
served the expression level of p31comet in several cancer
cell lines (Figure 6a). Cycling cells were subjected to
western blotting analysis, and monitored the p31comet,
Mad2, and APC2 protein levels. The protein levels of
Mad2 and p31comet in the indicated cell lines showed
great variations. Quantitative analysis of the Mad2 and
p31comet protein expression was performed using the in-
tensity of the APC2 loading control as a standard. Each
protein level was normalized to the expression level in
HeLa cells (p31comet/Mad2 ratio in HeLa cells = 1). The
quantitative p31comet/Mad2 expression ratios were
shown in Figure 6a. In U2OS, PC3, and HepG2 cells, the
p31comet/Mad2 expression level ratio was higher than in
other cell lines. However, in HEK293 and HT-29 cells,
the p31comet/Mad2 expression level ratio was lower,
although the p31comet signal was not detected in HT-29
cells. In A549, HCT116, DLD-1, MCF7, and SK-N-SH
cells, the p31comet/Mad2 expression level ratio was equal
to in HeLa cells. Using U2OS, HEK293, and HeLa cell
lines, we tested the sensitivity to taxol. Consistent
with the p31comet/Mad2 expression level ratio profile(Figure 6a), HEK 293 cellines were more sensitive to
taxol than HeLa and U2OS cells (Figure 6b). U2OS cell-
lines, whicih had a higher p31comet expression level, were
more resistant against taxol than HeLa cells at higher
concentrations (0.4-1 μg/ml) of taxol (Figure 6b). These
results indicated that the p31comet/Mad2 expression level
ratio may contribute to sensitivity to spindle poisons in
cancer cells.
Discussion
p31comet can abolish the Mad2-dependent SAC
We previously reported that the p31comet-Mad2 complex
becomes prominent in mid-mitosis and that the overex-
pression of p31comet in HeLa cells arrested by nocoda-
zole abrogates the arrest that is maintained by the SAC
because of the disappearance of the Cdc20-Mad2 com-
plex (Habu et al. 2002). The position between amino
acids 55 and 81 of p31comet might be responsible for
binding to Mad2 protein. A fine crystal study (Yang
et al. 2007) and Westhorpe et al. (2011) showed that
p31comet binds to Mad2 protein through multiple points
of interaction and that Q83A and F191A mutations in
p31comet can abolish Mad2-p31comet binding. Because
p31comet C fragment (81-274aa) contained the Q83 pos-
ition amino acid and was close to the interaction-
surface, which forms a coiled-coil structure, this mutant
may disrupt the p31comet structure and, making the mu-
tant unable to override nocodazole-induced SAC. Our
preliminary results showed that an L76A/L77A mutant
of p31comet could not override the Mad2-dependent SAC
and then a fragment of p31comet containing amino acid
1-80, which can bind to Mad2, could override
nocodazole-induced SAC (Additional file 1: Figure S1).
The 1-81 amino acid fragment of p31comet could bind to
Mad2 more strongly than other regions of p31comet by
two-hybrid assay. These results indicated that the
amino-terminal region of p31comet might maintain the
binding to Mad2 and regulate functional structure des-
pite the lack of conservation between other p31comet
homologs.
We have shown that the overexpression of p31comet
caused premature destruction of Securin and did not ac-
cumulate phosphorylated form of Cdc27 despite the
presence of anti-mitotic drugs. The abrogation of the ar-
rest maintained by the SAC was observed in cells treated
Figure 6 The effect of p31comet expression levels on drug resistance cancer cell lines. (a) Western blotting analysis of p31comet expression
levels in cancer cell lines. Each cell extract was subject to western blotting with anti-p31comet antibody, anti-Mad2 and anti-Cdc20 antibodies to
monitor SAC components, anti-EB1 and anti-α-Tubulin antibodies to monitor microtubule components, and anti-APC2 antibody for a loading
control. The quantitative p31comet/Mad2 expression level ratios were shown. (b) Cell viability analysis of cancer cell lines against taxol. Each cancer
cell lines with different levels of p31comet was treated with the indicated concentration of taxol and subject to trypan blue exclusion to counte
live cells at 2 days. Two hundred cells were scored at each point.
Habu and Matsumoto SpringerPlus 2013, 2:562 Page 11 of 15
http://www.springerplus.com/content/2/1/562with Hec1 siRNA, which caused Mad2-dependent mi-
totic arrest, but not AuroraA siRNA (Additional file 1:
Figure S6) (Martin-Lluesma et al. 2002; Jiang et al.
2003). An immuno-localization study and ectopic ex-
pression of Myc or GFP-tagged p31comet in HeLa and
PtK2 cells showed that p31comet was localized on kineto-
chores during prometaphase to metaphase (Westhorpe
et al. 2011). These results indicated that the overexpres-
sion of p31comet abolishes the Mad2-dependent SAC in a
Mad2-kinetochore localization-dependent manner. Sur-
prisingly, cells overexpressing p31comet cannot exit
mitosis in the absence of Eg5 activity through the Mad2-
dependent SAC, although the overexpression of p31comet
can abolish the Mad2-dependent SAC and monastrol-
induced mitotic arrest is abrogated by treatment with
Mad2 siRNA. Interestingly, the Mad2 protein regulatedthe SAC and the normal timing of mitotic progression,
but it did not regulate other SAC proteins, including
Mad1 and Bub3 (Meraldi et al. 2004). Therefore, we
speculated that mitotic progression is monitored by
Mad2 protein and that Eg5 function may be required for
the coordination of mitosis when p31comet is overex-
pressed in the cells with functional Mad2 protein and/or
normal levels of Mad2. Conversely, mitotic progression
is accelerated in the absence of functional Mad2 protein
and/or lower levels of Mad2 protein. Moreover, monas-
trol inhibits Eg5 kinesin function, but not microtubule
metabolism, which contrasts with the action of other
anti-mitotic drugs. Actually, p31comet overexpression in
the absence of anti-mitotic drugs did not show any mi-
totic errors and aneuploid cells in HeLa cells. siRNA
studies showed that in the absence of p31comet in HeLa
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delayed compared to normal mitosis (Westhorpe et al.
2011; Varetti et al. 2011; Jia et al. 2011; Hagan et al.
2011). Under normal microtubule environments,
p31comet might be able to override only SAC, but not
mitotic spindle organization and progression.
Interestingly, the overexpression of AuroraA kinase
overrides SAC, and induces resistance to taxol (Anand
et al. 2003), and binds to Cdc20 protein (Farruggio et al.
1999). In Xenopus, Eg2 (AuroraA) and Eg5 formed a
complex in mitosis (Giet et al. 1999). When AuroraA
was depleted by siRNA in HeLa cells, the overexpression
of p31comet did not abolish the nocodazole-induced SAC
(Additional file 1: Figure S6). My preliminary results
showed that p31comet localizes to centrosomes in pro-
phase (data not shown). From these observations, we
speculate that p31comet may function with AuroraA kin-
ase and Eg5 kinesin in mitotic events. This indicates that
inhibiting Eg5 kinesin function may be useful for cancer
therapies of cancer cells that have abbreviations in SAC.
p31comet overexpression and nocodazole and taxol
sensitivity
We showed here that p31comet overexpression caused
aneuploidy following the abrogation of a sustained SAC
and led to resistance to nocodazole and taxol in HeLa
and HCT116 cells. Strikingly, these resistant cells against
nocodazole and taxol were also the resistant to apoptotic
cell death induced by continuous drug treatment. Inter-
estingly, CDK1 activity is required for promotion of
apoptosis after SAC activation with spindle poisons, and
the apoptosis occurred after rereplication and abnormal
mitosis (Chan et al. 2008). The overexpression of
p31comet in HeLa cells arrested by nocodazole abrogates
SAC following degradation of cyclinB1 and Securin. Col-
lectively, these data indicate that the overexpression of
p31comet in human cells shows similar effect with treat-
ment with CDK inhibitors. Chromosomal instability has
been thought to be linked to defects in SAC in human
cancers and associated with tumorigenesis and/or pro-
gression. Increasing evidence has shown that a loss of
SAC regulation causes premature exit from mitosis and
subsequently leads to chromosomal instability (Weaver
and Cleveland 2005). However, alterations in the expres-
sion levels in SAC genes were reported in human can-
cers (Hanks et al. 2004; Cheung et al. 2005; Kienitz et al.
2005; Kim et al. 2005). Furthermore, decreased Mad2
expression level has led to increased chemosensitization
to spindle poisons such as vincristine. The p31comet gene
locus was mapped to chromosome 6p21.1 and cytogen-
etic abnormalities of 6p21.1, including amplifications,
deletions, and translocations, have been reported in
osteosarcoma (Dobles et al. 2000; Hanks et al. 2004;
Burds et al. 2005), mature B cell malignancies (Sonokiet al. 2001) and squamous cell carcinoma (Brass et al.
1996; Mazurenko et al. 1999; Wang et al. 2003; Cheung
et al. 2005; Jin et al. 2012). Ma et al. reported that the
sensitivity to spindle poisons was enhanced and spindle
poison-induced cell death was elevated in p31comet-de-
pleted HeLa cells. Therefore, we speculate that the
expression level of p31comet may contribute to SAC-
dependent chromosomal instabilities in human cancers.
Furthermore, we showed here that aneuploidy and re-
sistance to spindle poisons caused by the overexpression
of p31comet is a p53-independent adaptation pathway in
culture cells. Mad2 and p53 double knockout cells can
survive, but the same is not true for Mad2 single
knockout cells (Dobles et al. 2000; Burds et al. 2005).
Using various cancer cell lines, p31comet/Mad2 protein
expression ratio appears to contribute taxol-resistance
(Figure 6). Cdc20 protein expression level was also vari-
able in used cancer cells lines, but Cdc20/Mad2 protein
expression ratio seems to be dispensable for taxol resist-
ance compared to p31comet/Mad2 ratio. Similar result
was indicated that the expression of p31comet and Mad2
correlated with timing of mitotic slippage in various can-
cer lines (Ma et al. 2012). Therefore, the expression level
of p31comet may contribute to chromosomal instabilities
in cells with a functional SAC and functional p53 check-
point machinery at the initial stage of tumorigenesis.
Methods
Cell culture, and adenovirus transduction, and siRNA
transfection
HeLa, HEK293, 293A, and MCF7 cells were grown
under standard conditions in DMEM supplemented with
10% FBS and penicillin and streptomycin. A549, DLD-1,
H1299, HCT116, HepG2, HT-29, PC3, SK-N-SH, and
U2OS cells were grown under standard conditions in
RPMI medium supplemented with 10% FBS and penicil-
lin and streptomycin. N-terminus fused EGFP-Mad2 in
the pEGFP-C1 plasmid was introduced into HeLa cells
and selected with G418 (Life Technologies, Carlsbad,
CA). Cells stably expressing EGFP-Mad2 were con-
firmed by observation with fluorescence microscopy and
western blotting with anti-GFP (Roche Applied Science,
Mannheim, Germany) and anti-Mad2 (Covance Inc.,
Princeton, NJ) antibodies.
Recombinant adenoviruses were produced using the
ViraPower adenovirus kit (Life Technologies) according
to the manufacturer’s protocol. Amplified recombinant
adenovirus was titrated, and the expression of the
EGFP-fused gene was monitored. EGFP and EGFP-fused
p31comet (full (amino acids 1-274), A (31-274), B
(55-274), C (81-274), and D (108-274)) were cloned
into the pENTR4 plasmid (Life technologies). These
plasmids were recombined with the pAd-CMV/DEST
plasmid (Life Technologies) using LR-ClonaseII (Life
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293A cells, and recombinant adenovirus was produced.
To express EGFP or EGFP-p31comet protein in HeLa
cells, 1 × 105 cells were seeded into 6 wells plate before
transduction with adenovirus and were incubated 24 h
with adenovirus at multiplicity of infection = 5. After the
incubation, cells were washed with fresh DMEM con-
taining 10% FBS, and added fresh medium with the indi-
cated concentrations of nocodazole (Merk, Darmstadt,
Germany) or taxol (Tocris Bioscience, Bristol, UK) or
monastrol (Tocris) was added. After the further incuba-
tion for 24 h, cells were collected and analyzed. siRNA
duplexes to repress Eg5 (#8100064834, QIAGEN GmbH,
Hilden, Germany), control (#1027280, QIAGEN), and
Mad2 (#SI02653735, QIAGEN) were transfected using
Nucleofector device and transfection reagent (Lonza,
Visp, Switzerland) according to the manufacturer’s in-
structions. In brief, 106 cells were collected and washed
with fresh medium. The cells were resuspended in
100 μL transfection reagent, mixed with siRNA du-
plexes, and transfected with a Nucleofector device. The
cells were seeded in wells of a 6-well plate; after 6 h or
12 h, 1.5 × 105 cells were replated in wells of a 6-well
plate. Cells were analyzed 24-60 h after transfection.
Immunoprecipitation and western blotting
Harvested cells were washed once with phosphate buff-
ered saline (PBS, pH 7.2) without calcium and magne-
sium and lysed in nonidet p-40 (NP-40) lysis buffer
(50 mM Hepes, pH 7.4, 250 mM NaCl, 1% NP-40,
5 mM ß-glycerophosphate, 1 mM phenylmethylsulfonyl
fluoride, 2 mM Na3VO4, 0.2 mM ethylenediaminetetra-
acetic acid (EDTA), 10 mM NaF, 1 mM dithiothreitol
and protease inhibitor cocktail (Nacalai, Kyoto, Japan).
Cell lysates were incubated at 0°C for 20 min and centri-
fuged at 8,500 ×g for 15 min. For immunoprecipitation,
the supernatants were incubated with anti-GFP antibody
conjugated with agarose beads (MBL, Nagoya, Japan) for
4 h at 4°C. The immunoprecipitates were washed once
with NP-40 lysis buffer, washed twice with NP-40 lysis
buffer without NaCl, and subjected to western blot.
Antibodies to p31comet (Habu et al. 2002) or GFP
(Roche) were used at a concentration of 0.5 μg/mL. The
antibody to Mad2 (Covance) was used at the recom-
mended dilution. Other antibodies, anti-Cdc27 (BD
Biosciences, Franklin Lakes, NJ), anti-Cdc20 (Life Tech-
nologies), anti-a-Tubulin (Sigma, St. Louis, MO), anti-
Eg5 (BD Biosciences), anti-EB1 (BD Biosciences), and
anti-Securin and anti-APC2 (Life Technologies), were
used at a concentration of 1 μg/mL.
FACS analysis, apoptosis assay, and cell survival assay
FACS analysis was performed with a standard method,
and fluorescence was measured with a Guva PCAinstrument (GE Healthcare, Uppsala, Sweden). The
apoptosis assay was performed with a Guva MultiCas-
pase detection kit (GE Healthcare) using a Guva PCA
instrument. Dead cells including early to late apoptotic
cells and dying cells, were measured to distinguish them
from live cells. The survival assay was performed with
trypan blue exclusion. EGFP- or EGFP-p31comet overex-
pressing cells (1 × 105 cells/ sample) were plated in
24 wells dish (2 × 102 cells/well) and treated with each
drug for the indicated time. The cells were dislodged
and stained with trypan blue dye (Sigma), and the un-
stained cells were counted for cell survival.
Cell staining
Cells grown on poly-L-lysine–coated cover slips were
washed with PHEM buffer (60 mM Pips, 25 mM Hepes,
pH 6.9, 10 mM EDTA, 4 mM MgCl2) and permeabilized
with 0.2% Triton X-100 in PHEM for 2 min on ice. The
cells were fixed with 4% formaldehyde in PHEM buffer for
20 min on ice to visualize EGFP-Mad2. To stain microtu-
bules, the cells were fixed and permeabilized in cold
methanol for 2 min. The cells were washed twice with
PHEM and blocked with heated goat serum. The cells
were incubated with anti-α-tubulin antibody (Sigma) con-
jugated with Cy3. DNA was visualized with 50 ng/mL of
Hoechst 33324 (Nacalai, Kyoto, Japan) for 5 min.
Additional file
Additional file 1: Figure S1. Relationship between the N-terminal
region of p31comet and abrogation of the nocodazole induced SAC.
Figure S2. Monastrol induced Mad2-dependent mitotic arrest. Figure
S3. Overexpression of p31comet could not override monastrol induced
Mad2-dependent mitotic arrest. Figure S4. Overexpression of p31comet
induced abnormal nuclei and giant cells. Figure S5. Overexpression of
p31comet could override the taxol-induced SAC, but not Nocodazole-
induced SAC in H1299 cells. Figure S6. Overexpression of p31comet in
Hec1 or AuroraA-knockdown in HeLa cells.
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